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SUMMARY
While VEGF-targeted therapies are showing promise, new angiogenesis targets are needed to
make additional gains. Here, we show that increased Zeste homologue 2 (EZH2) expression in
either tumor cells or in tumor vasculature is predictive of poor clinical outcome. The increase in
endothelial EZH2 is a direct result of VEGF stimulation by a paracrine circuit that promotes
angiogenesis by methylating and silencing vasohibin1 (VASH1). EZH2 silencing in the tumor-
associated endothelial cells inhibited angiogenesis mediated by reactivation of VASH1, and
reduced ovarian cancer growth, which is further enhanced in combination with EZH2 silencing in
tumor cells. Collectively, these data support the potential for targeting EZH2 as an important
therapeutic approach.
SIGNIFICANCE
In this work, we identify EZH2 as a key regulator of tumor angiogenesis. The increase in
endothelial EZH2 is a direct result of VEGF stimulation and indicates the presence of a paracrine
circuit that promotes angiogenesis. EZH2 silencing in the tumor-associated endothelial cells using
siRNA, packaged in the chitosan delivery system, resulted in significant growth inhibition in an
orthotopic ovarian cancer model. EZH2 silencing in tumor endothelial cells resulted in decreased
angiogenesis that was mediated by increased levels of the angiogenesis inhibitor, vasohibin1
(VASH1). Combined, these data provide a significant conceptual advance in our understanding of
the regulation of angiogenesis in ovarian carcinoma and support the potential for targeting EZH2
as a therapeutic approach.
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INTRODUCTION
Targeting the tumor vasculature is a particularly attractive strategy because of the presumed
genetic stability of endothelial cells (Folkman, 1990). Anti-angiogenic therapeutic strategies
are predicted to be meritorious in ovarian cancer patients based on tumor and endothelial
VEGF overexpression, and response characteristics noted in phase II clinical trials (Burger
et al., 2007; Jain et al., 2006; Spannuth et al., 2008). As such, 7 phase III clinical trials in
primary and recurrent disease have completed enrollment or are accruing. However, despite
initial responses, most patients eventually experience disease progression. The mechanism
for this acquired resistance is not well described, but appears to be due in part to expansion
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or expression of redundant (Relf et al., 1997) alterations in maturing vasculature (Huang et
al., 2004) and epigenetic mechanisms (Kerbel, 2001a; Kerbel et al., 2001b); therefore, new
anti-angiogenesis targets are needed.
In search of such targets, we carried out genomic profiling studies of endothelial cells from
epithelial ovarian cancer and from their normal counterparts (Lu et al., 2007a). Among the
many genes with increased expression in tumor endothelial cells, we focused on the
enhancer of Zeste homologue 2 (EZH2), a member of the polycomb-group (PcG) proteins.
PcG proteins are negative regulators of gene expression and are involved in the stable
transmission of the repressive state of their target gene throughout the cell cycle (Cavalli and
Paro, 1998; Kingston et al., 1996; Simon, 1995). EZH2, a critical component of the
polycomb repressive complex 2 (PRC2), has intrinsic histone methyl transferase (HMTase)
activity and has been implicated in the progression and metastasis of several cancers (Cha et
al., 2005; Raman et al., 2005). For instance, normalized EZH2 mRNA transcripts were
significantly associated with invasiveness of bladder tumors and were significantly higher in
grade 3 versus grade 1 and 2 tumors (Weikert et al., 2005). Similar relationships have been
described in breast (Kleer et al., 2003), prostate (Varambally et al., 2002), gastric
(Matsukawa et al., 2006) and squamous cell cancers of the oral pharynx (Kidani et al.,
2009). The association of EZH2 with the malignant phenotype of many solid tumors and its
function as a repressor of gene targets led to the hypothesis that EZH2 could impact specific
angiogenic mechanisms of endothelial cell biology. Herein, we focused on EZH2 mediated
regulation of vasohibin1 (VASH1), which is an endothelial cell specific and intrinsic
negative regulator of angiogenesis (Hosaka et al., 2009; Watanabe et al., 2004).
RESULTS
EZH2 expression in human ovarian carcinoma
We first examined the clinical significance of EZH2 in 180 epithelial ovarian cancers.
Increased tumoral EZH2 (EZH2-T) expression, based on the histochemical score, was noted
in 66% of samples and increased expression in the vasculature (EZH2-Endo) was noted in
67% of the samples (Figures 1A and 1C). Increased expression of EZH2-T and EZH2-Endo
was significantly associated with high-stage (p < 0.001) and high-grade (p < 0.05; Table 1)
disease. Increased EZH2-T was significantly associated with decreased overall survival
(median 2.5 years vs. 7.33 years, p < 0.001; Figure 1B). Similarly, EZH2-Endo was
predictive of poor overall survival (2.33 vs. 8.33 years, p < 0.001; Figure 1D). On the basis
of pathway-analysis predictions from our genomic profiling data comparing endothelial cells
from epithelial ovarian cancer with those from normal ovarian tissues (Lu et al., 2007a), we
next examined potential associations between EZH2 and VEGF expression, and microvessel
density (MVD). Tumors with increased VEGF expression had significantly greater
prevalence of increased EZH2-Endo expression (p < 0.001; Figures 1E and 1F). Moreover,
tumors with increased EZH2-Endo expression had significantly greater MVD (p < 0.001 by
Wilcoxon ranked sums test; Figures 1G and 1H).
VEGF increases EZH2 levels in endothelial cells
On the basis of our observations from clinical samples, we next asked whether VEGF could
directly regulate EZH2 levels in endothelial cells. For these experiments, mouse ovarian
endothelial cells (MOEC) were co-transfected with the Renilla luciferase plasmid and firefly
luciferase plasmid either with or without the EZH2 promoter construct. Cells were then
treated with VEGF, or conditioned media from SKOV3 ovarian cancer cells (SKOV3-CM).
There was a significant increase in EZH2 promoter activity in endothelial cells in response
to VEGF, and conditioned media (Figure 1I). To examine changes in EZH2 message,
MOECs were treated as indicated above and EZH2 mRNA was quantified using real time
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RT-PCR. EZH2 mRNA expression levels were significantly increased in endothelial cells in
response to VEGF, or SKOV3-CM (Figure 1I). The increases in EZH2 promoter activity
and mRNA levels in response to SKOV3-CM or VEGF were blocked with the VEGFR2
specific antibody DC101. Similarly, increased EZH2 protein levels in response to VEGF
were blocked by the anti-VEGFR2 antibody (Figure S1A).
Since EZH2 levels were noted to be increased in tumor and tumor-associated endothelial
cells, we next asked whether there was a correlation between the two compartments in
human ovarian carcinoma. Orthogonal regression modeling between these factors described
a high coefficient of correlation (r=0.83, p < 0.001; Figure S1B). To address whether tumor
derived VEGF affected endothelial EZH2, we utilized an orthotopic model of ovarian cancer
metastasis. SKOV3ip1 tumor bearing animals were treated with either control antibody or
bevacizumab (selective for human VEGF). Following treatment for 2 weeks, the tumors
were harvested and tumor and endothelial cells were isolated. Compared to normal
endothelial cells, EZH2 levels were significantly higher in the tumor endothelial cells, and
this increase was substantially reduced in the bevacizumab treated samples (Figure S1C).
Conversely, bevacizumab had no effect on tumor cell EZH2 levels (Figure S1D). To
examine for direct effects of EZH2 on endothelial cells, we transfected EZH2 into MOEC,
and examined for effects on tube formation using in vitro assays. Compared to empty vector
controls, EZH2 promoted tube formation (p < 0.01), which was only minimally blocked by a
VEGFR2 inhibitor (Figure S1E). Similar results were noted with HUVECs (data not
shown).
EZH2 silencing increases VASH1 in endothelial cells
To determine the mechanism by which EZH2 could promote angiogenesis, we searched a
database from a whole genome ChIP-on-ChIP analysis that was performed in a separate
study. We found that an anti-angiogenic gene, VASH1, directly binds to EZH2. To validate
this finding, we performed a ChIP assay of EZH2 for the VASH1 promoter in endothelial
cells in the presence or absence of VEGF (Figure 2A), which confirmed direct EZH2
binding to the VASH1 promoter. Quantitative ChIP analysis confirmed the enhanced
binding of EZH2 to the VASH1 promoter in response to VEGF (Figure 2B). Next, we
silenced the EZH2 gene in MOECs using two different siRNA sequences (Figure 2C),
which resulted in a 3.6-3.8 fold increase in VASH1 (Figure 2D). Moreover, there was a
significant increase in VASH1 promoter activity following EZH2 gene silencing (Figure
S2).
To determine the mechanism by which EZH2 regulates VASH1, we performed methylation
specific PCR to detect VASH1 methylation in endothelial cells in the presence of VEGF
after silencing EZH2. We found that VEGF treatment resulted in a 1.7 fold increase in
VASH1 methylation compared to the controls (Figure 2E). However, EZH2 silencing
resulted in a 3.3 fold decrease in VASH1 methylation in the VEGF-treated MOECs. EZH2
gene silencing also decreased histone 3 methylation at lysine 27 by 2.5-fold in endothelial
cells (Figure 2F).
E2F mediated regulation of EZH2 in endothelial cells
It is known that VEGF can activate E2F transcription factors (Zhu et al., 2003). Due to their
suspected role in regulating EZH2 levels, we first tested the effect of VEGF on E2F1-5 in
MOECs. There was a significant increase in E2F1 and E2F3, but not others, following
treatment with VEGF (Figure 3A). To determine which E2F transcription factors might be
responsible for increasing EZH2 levels, we next examined the effects of VEGF after
silencing either E2F1 or 3. EZH2 levels were significantly decreased in E2F1 and E2F3
silenced cells (Figure 3B). To validate the binding of EZH2 promoter to E2F1 and/or E2F3
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transcription factors, we performed ChIP assays of EZH2 to these transcription factors. As
shown in Figure 3C, E2F1 and E2F3 bind directly to the EZH2 promoter, demonstrating that
EZH2 is a direct target of the E2F transcription factors (Wu et al., 2010). Moreover, the
VEGF mediated binding of EZH2 to the VASH1 promoter was abrogated with E2F1 or
E2F3 gene silencing (Figure 3D).
To determine the functional role of VASH1 in angiogenesis, we performed migration and
tube formation assays using MOECs following VASH1 gene silencing using two different
siRNA sequences. Both cell migration and tube formation were significantly increased after
VASH1 gene silencing (Figures S3A and S3B). Similar results were obtained with HUVEC
(data not shown).
In vivo EZH2 gene silencing
On the basis of our in vitro findings, we next asked whether EZH2 gene silencing in vivo
would affect tumor growth and angiogenesis. Before conducting the EZH2 targeted in vivo
experiments, we developed and characterized chitosan (CH) nanoparticles for systemic
delivery of siRNA into both tumor cells and tumor-associated vasculature. Several
formulations of CH with siRNA (siRNA/CH) were tested (Figure S4A) and optimized
(Figures S4B-S4I) and the 3:1 ratio (CH:TPP) nanoparticles showed the greatest (75%)
incorporation efficiency (Figure S4D). Therefore, for all subsequent experiments, we used
the siRNA/CH3 nanoparticles due to their small size, slight positive charge, and high
incorporation efficiency of siRNA.
Prior to performing proof-of-concept in vivo efficacy studies, we tested the efficiency of
siRNA delivery into orthotopic ovarian tumors. Non-silencing siRNA labeled with
Alexa-555 was incorporated into CH nanoparticles and injected intravenously (i.v.) into
mice bearing HeyA8 orthotopic tumors (17 days after intraperitoneal (i.p.) inoculation of
tumor cells). Tumors were harvested at 15 hours and 3, 5 or 7 days (3 mice per time point)
following injection and examined for extent of siRNA delivery. At all time points, punctated
emissions of the siRNA were noted in the perinuclear regions of individual cells. SiRNA
was noted in >80% of fields examined following a single intravenous injection. To confirm
delivery of siRNA in the vasculature, slides were also stained for CD31. Indeed, siRNA was
delivered into the tumor-associated endothelial cells, suggesting potential applications for
targeting the tumor vasculature (Figure 4A). To confirm intracellular delivery of siRNA, we
created 3-dimensional reconstructions of the tumors using confocal microscopy. Lateral
views of the optical sections clearly demonstrated the presence of siRNA within the tumor
cells (Figure 4B). However, very little siRNA was taken up by macrophages as determined
by labeling tissues with f4/80 (Figure S4J).
To examine the biodistribution of siRNA into other organs, sections of liver, lung, kidney,
heart, spleen and brain were also examined, and siRNA delivery was detected in most of
these organs (Figure S4K). We also utilized optical imaging to assess biodistribution.
Fluorescence corresponding to siRNA uptake was seen in tumor and various organs, such as
kidney, liver, lung, and spleen (Figure 4C). Semi-quantitative assessment of fluorescence
confirmed increased uptake of siRNA in HeyA8 tumors and various organs in mice injected
intravenously with Cy 5.5 labeled siRNA/CH compared to those injected with unlabeled
siRNA/CH (Figure 4D). To examine the in vivo effects of EZH2 gene silencing on tumor
growth, we utilized EZH2 siRNA directed to either the human (tumor cells; EZH2 Hs
siRNA/CH) or mouse (endothelial cells; EZH2 Mm siRNA/CH) sequence. The expression
levels of EZH2 in ovarian cancer cells are shown in Figure S5A; the specificity of siRNA
was confirmed by testing each siRNA in both MOEC and human tumor (HeyA8) cells
(Figure S5B). Following intravenous injection of either control siRNA/CH, EZH2 Hs
siRNA/CH, EZH2 Mm siRNA/CH, or the combination of EZH2 targeted siRNAs into
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HeyA8 tumor-bearing mice (n=3 mice per group at each time point), tumors were harvested
at different time points and examined for EZH2 protein levels. EZH2 levels were decreased
by 24 hours following single injection of EZH2 Hs siRNA/CH with return of expression to
baseline expression levels after 96 hours (Figure 5A). EZH2 gene silencing was also
confirmed with real-time RT-PCR analysis of tumor and endothelial cells (Figure S5D and
S5E).
To determine the localization of EZH2 silencing following siRNA/CH administration, we
performed dual immunofluorescence staining for EZH2 and CD31. This experiment further
demonstrated that EZH2 Hs siRNA/CH resulted in EZH2 silencing in the tumor cells
whereas EZH2 Mm siRNA/CH silenced EZH2 only in the tumor endothelial cells (Figure
5B). To determine the therapeutic efficacy of EZH2 gene silencing, a well-characterized
orthotopic model of ovarian carcinoma was utilized. Seven days following injection of
tumor cells into the peritoneal cavity, mice were randomly allocated to one of the following
groups (n=10 mice per group): 1) control siRNA/CH, 2) EZH2 Hs siRNA/CH, 3) EZH2 Mm
siRNA/CH and 4) combination of EZH2 Hs siRNA/CH plus EZH2 Mm siRNA/CH. Mice
were sacrificed when animals appeared moribund due to significant tumor burden (4 to 5
weeks after cell injection depending on the cell line). As shown in Figure 5C and Figure
S5C, in both models, treatment with EZH2 Mm siRNA/CH resulted in a significant decrease
in tumor burden compared to control siRNA/CH (62% reduction in HeyA8; p < 0.02 and
40% reduction in SKOV3ip1, p < 0.03). EZH2 Hs siRNA/CH as a single-agent had modest
effects on tumor growth (p < 0.04 for HeyA8; and p = 0.18 for SKOV3ip1) compared with
control siRNA/CH. However, the greatest reduction was observed with the combination of
EZH2 Hs siRNA/CH plus EZH2 Mm siRNA/CH (83% reduction in HeyA8, p < 0.001 and
65% reduction in SKOV3ip1, p < 0.001). To test for potential off-target effects, we tested
the efficacy of 3 additional mouse EZH2 siRNA sequences with similar effects on tumor
growth (data not shown).
To evaluate the effects of EZH2 on other parameters of tumor growth, we examined tumor
incidence and number of nodules (Table S1). The combination of EZH2 Hs siRNA/CH plus
EZH2 Mm siRNA/CH resulted in a significant reduction in tumor nodules in both HeyA8 (p
= 0.002 vs. control siRNA/CH treated group) and SKOV3ip1 tumors (p = 0.004 vs. control
siRNA/CH treated group). The decrease in tumor burden occurred despite having
comparable tumor incidence. The mean mouse body weight was similar among the different
groups (data not shown), suggesting that feeding and drinking habits were not affected.
Effect of EZH2 targeting on tumor vasculature and proliferation
To identify potential mechanisms underlying the efficacy of EZH2 silencing on ovarian
tumors, we examined its effects on several biological end points including MVD, pericyte
coverage (desmin) and cell proliferation (PCNA). EZH2 Mm siRNA/CH and the
combination therapy groups had significantly lower microvessel density (Figure 6A)
compared to the EZH2 Hs siRNA/CH and control siRNA/CH treated SKOV3ip1 tumors.
Pericyte coverage (assessed with desmin and alpha smooth muscle actin (ASMA) staining)
was increased in EZH2 Mm siRNA/CH and the combination groups compared to other 2
groups, suggesting greater vascular maturation (Figure 6A and Figure S6B). Combination
treatment with EZH2 Hs siRNA/CH and EZH2 Mm siRNA/CH also resulted in a significant
reduction in cell proliferation (Figure S6C) and increased apoptosis (Figure S6C). Similar
effects of EZH2 silencing on MVD, pericyte coverage, and proliferation were noted in the
HeyA8 model (Figure S6D). To test the effect of EZH2 gene silencing on intratumor
hypoxia, we measured viable hypoxic areas by staining tumor sections with pimonidazole.
Compared to control siRNA/CH treated tumors, EZH2 Mm siRNA/CH treated tumors had
modest increase in hypoxia (Figure S6E and S6F), which is consistent with effects of
decreased angiogenesis.
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VASH1 levels were significantly increased following EZH2 gene silencing in the tumor
endothelial cells (Figure S6A). To determine the requirement for VASH1 in mediating the
anti-tumor effects of EZH2 silencing, we examined the effects of VASH1 silencing in
combination with EZH2 Mm siRNA/CH. The anti-tumor effect of EZH2 silencing in the
tumor vasculature was completely reversed by VASH1 silencing (Figure 6B and Table S2),
indicating that VASH1 is required for mediating the anti-tumor effects of EZH2 silencing.
To determine if endothelial EZH2 expression is related to VASH1 expression in human
epithelial ovarian cancer, 37 samples were also immunostained for VASH1. The best-fit
linear regression model demonstrated a significant inverse relationship (R2= −0.59; p <
0.001) between endothelial EZH2 and VASH1 scores (Figure 6C). Specifically, presence of
high EZH2 expression was associated with low VASH1 expression, which was otherwise
elevated in the absence of or in the presence of low EZH2 expression. We also examined
mRNA levels of EZH2 and VASH1 in endothelial cells isolated from 3 normal ovarian and
10 epithelial ovarian cancer samples using quantitative RT-PCR. Compared to normal
ovarian endothelial cells, VASH1 levels were significantly lower in samples with high
versus low EZH2 levels (Figure 6D). To assess vessel maturation (pericyte coverage), the 37
human ovarian cancer samples were immunostained for ASMA. Tumors with low
endothelial EZH2 had a significantly higher percentage of blood vessels with pericyte
coverage (p < 0.01; Figure 6E).
To identify potential direct effects of EZH2 gene silencing on tumor cells, we performed a
series of in vitro assays. EZH2 siRNA reduced migration by 64 to 71% (p < 0.01), and
invasion by 63 to 72% (p < 0.01) in the SKOV3ip1 cells (Figures S5F-S5G). There were no
significant effects on cell viability (Figure S5H). Similar results were noted with the HeyA8
cells (data not shown). To address the potential effects of tumor cell EZH2 gene silencing on
invasion in vivo, we injected SKOV3ip1 tumor cells directly into the ovary and the animals
were randomly allocated to the following groups (n=10 mice per group): 1) control siRNA/
CH, 2) EZH2 Hs siRNA/CH. Following 4 weeks of treatment, the mice were dissected and
the aggregate tumor weight was 30% lower (p = 0.03) in the EZH2 Hs siRNA/CH treated
animals. While 50% of the mice in the control group developed para-aortic lymph node
metastasis, none had nodal metastasis in the EZH2 Hs siRNA/CH group (p < 0.001).
Moreover, the ovarian tumors in the control Hs siRNA/CH group had a more infiltrative
growth pattern compared to the EZH2 Hs siRNA/CH group (Figure S5I). To identify genes
potentially affected by EZH2 in ovarian cancer cells, we performed genomic analyses of
SKOV3ip1 cells following treatment with either control or EZH2 siRNA. There were 788
genes with significantly increased or decreased expression (Figure S5J). Among these, gene
networks of connective tissue growth factor (CTGF) were significantly reduced, which are
known to regulate tumor cell migration and invasion (Figure S5K) (Chu et al., 2008; Cicha
and Goppelt-Struebe, 2009).
DISCUSSION
Our results describe a mechanism by which VEGF increases EZH2 levels in the tumor
vasculature. EZH2, in turn, contributes to tumor angiogenesis by inactivating the anti-
angiogenic factor, VASH1, by methylation. These results coupled with pathway-analysis
predictions of genomic profiling data of tumor endothelial cells (Lu et al., 2007a) expand
our understanding of tumor angiogenesis (Figure 7). Moreover, we have developed and
characterized a highly effective method of gene silencing in tumor cells as well as in the
blood vessels that support their growth.
PcG proteins play a critical role in determining cell fate during both normal and pathologic
processes. Two separate subsets of PcG complexes (PRC1 and PRC2) have been described
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in humans (Cao and Zhang, 2004). PRC1 is thought to be involved in maintenance of
repression, whereas PRC2 plays a role in initiating repression. The PRC2 complex consists
of the EZH2, EED, and SUZ proteins (Cao and Zhang, 2004). Altered expression of these
proteins has been implicated in cancer pathogenesis (Raman et al., 2005; Cao and Zhang,
2004). However, prior to our work, the role of EZH2 in angiogenesis was not known.
Angiogenesis is regulated by the balance of various pro-angiogenic stimulators, such as
VEGF, and several angiogenesis inhibitors such as angiostatin, and endostatin (Folkman,
1990). On the basis of findings from genomic profiling of endothelial cells from ovarian
cancer versus those from normal ovaries, we discovered that EZH2 expression is
significantly increased in tumor-associated endothelial cells (Lu et al., 2007a). VEGF is well
recognized as a pro-angiogenic factor in ovarian and other cancers (Spannuth et al., 2008),
and its receptors are expressed by endothelial and other cell types including tumor and
perivascular cells (Spannuth et al., 2009). In the current study, we showed that VEGF can
directly increase EZH2 levels in endothelial cells, which in turn inactivates a potent anti-
angiogenic factor, VASH1. Silencing EZH2 gene resulted in demethylation of VASH1 in
endothelial cells. This finding is consistent with the role of EZH2 in controlling DNA
methylation of EZH2-targeted genes concomitant with reducing H3K27 (McGarvey et al.,
2007). VASH1 is known to inhibit endothelial-cell migration, proliferation, and tube
formation (Shen et al., 2006). VASH1 expression can be induced by VEGF as part of a
negative feedback mechanism in endothelial cells (Hosaka et al., 2009; Tamaki et al., 2009;
Watanabe et al., 2004; Yoshinaga et al., 2008). VASH1 limits tumor-associated
angiogenesis and increases vessel maturity (Kern et al., 2009). Since VASH1 levels are low
in the setting of high EZH2, VASH1 siRNA alone had no significant effect on tumor
growth. However, VASH1 levels in tumor endothelial cells are increased in response to
EZH2 gene silencing, and VASH1 siRNA blocked the inhibitory effects of EZH2 gene
silencing on tumor growth.
A number of therapeutic anti-angiogenic targets have recently emerged supporting the
clinical rationale of exploiting tumor and endothelial cell interactions. The most mature and
promising among ovarian cancer patients involves VEGF and its receptors. For instance,
bevacizumab, a chimeric monoclonal antibody targeting VEGF-A has demonstrated
impressive single agent activity (objective response and non-progression at 6 months) in
recurrent ovarian cancer patients and more recently, significant efficacy (PFS) in
combination with chemotherapy administered in the frontline adjuvant setting (Burger et al.,
2007; Burger et al., 2010). However, this compound and others in its class indiscriminately
target VEGF, leading to a number of clinically significant and sometimes lethal side effects
(Stone et al., 2010). In addition, new strategies targeting angiogenesis are needed as the
above therapies are rarely curative and a growing population of patients are demonstrating
VEGF resistance. EZH2 represents an innovative strategy, which has activity on both tumor
cells and tumor-associated vasculature. The differential expression between normal and
tumor vasculature may be hypothesized to have less off-target associated toxicity.
Nevertheless, combinatorial approaches with VEGF targeting may augment efficacy and are
attractive for further preclinical exploration.
While a number of important targets in tumor and endothelial cells have been identified,
many of these are difficult to target with small molecule inhibitors and monoclonal
antibodies. This limitation prompted us to utilize RNA interference as a means to target
EZH2. We have recently demonstrated that a neutral nanoliposomal carrier allows efficient
systemic delivery of siRNA into orthotopic tumors (Landen et al., 2005; Thaker et al.,
2006). However, due to limited delivery of siRNA into the tumor-associated endothelial
cells with this approach, we sought to develop additional nanoparticles that would allow
siRNA delivery into both tumor and tumor-associated endothelial cells. Chitosan is desirable
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for biological applications due to properties such as low immunogenicity and low toxicity
(Kumar, 2000). These properties make use of chitosan for systemic in vivo siRNA delivery
highly attractive (Howard et al., 2006). Indeed, our data demonstrate highly effective
delivery of siRNA incorporated into chitosan nanoparticles into both tumor and tumor-
associated endothelial cells. Such an approach may add a powerful tool to the
armamentarium for targeting angiogenesis promoting genes.
In summary, molecular and genetic manipulations have identified EZH2 as a key regulator
of tumor angiogenesis here, but these effects do not rule out the possibility that EZH2 has
oncogenic functions in tumor cells (Cao and Zhang, 2004; Raman et al., 2005). For example,
EZH2 has been implicated in cellular transformation, proliferation, and avoidance of
apoptosis (Tonini et al., 2008). However, to the extent that targeting tumor endothelial cells
provides therapeutic benefit (Burger et al., 2007; Jain et al., 2006), interfering with EZH2 in
the tumor and endothelial cells might represent an important strategy for treatment of
ovarian and other cancers.
EXPERIMENTAL PROCEDURES
Cell lines and culture
The HeyA8 and SKOV3ip1 human epithelial ovarian cancer cells were maintained as
described previously (Kamat et al., 2007; Lu et al., 2007b). The derivation and
characterization of the mouse ovarian endothelial cells (MOEC) has been described
previously (Langley et al., 2003). HUVECs were purchased from Cambrex (Walkersville,
MD) and maintained with heparin and gentamicin/amphotericin-B, as previously described
(Ptasinska et al., 2007).
EZH2 promoter construct
The EZH2 promoter was amplified by PCR from the Roswell Park Cancer Institute human
BAC library 11, Clone-ID RP11-992C19 purchased from the Children’s Hospital Oakland
Research Institute (Oakland, CA), and then cloned into the pGL3-Basic Vector (Promega
Corp., Madison, WI). The EZH2 promoter construct was amplified using primers (see
Supplemental Experimental Procedures) with XhoI and HindIII restriction endonuclease
sites added to the ends. Purified PCR product was then cloned upstream of the luc+ gene in
the pGL3-Basic Vector (Promega Corp.).
Luciferase reporter assay
Relative activity of the EZH2 promoter in MOEC was determined by luciferase reporter
assays. Cells were transfected in low-serum medium (0.5% serum) with the firefly luciferase
plasmid, either empty vector (pGL3-Basic) or the EZH2 promoter construct vector
(EZH2prom-pGL3-Basic), in 12-well plates using Effectene® Transfection Reagent from
Qiagen (Valencia, CA). Cells were then maintained in low-serum medium for 18 hours,
washed in PBS, and treated in triplicate at 37°C for 6 hours. Treatments included
recombinant human rhVEGF165 (VEGF; 50 ng/mL; Peprotech, Rocky Hill, NJ), in fresh
medium plus 0.5% serum, and conditioned media from immortalized ovarian surface
epithelium (IOSE120) or SKOV3 ovarian cancer cells. Following treatment, cells were
washed and processed using the Dual-Luciferase® Reporter Assay System (Promega Corp.).
Chromatin immunoprecipitation (ChIP) assay
Cells were cultured in low serum medium (0.5% serum) for 18 hours after being transfected
with siRNA for 48 hours and then treated with or without VEGF (50 ng/mL) for 6 hours.
After treatment, ChIP assays were performed using EZ ChIPTM kit (Milllipore, Temecula,
CA) as described by the manufacturer. Briefly, cross-linked cells were collected, lysed,
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sonicated and subjected to immunoprecipitation with EZH2 antibody (Cell signaling) or
mouse IgG (mIgG) control. Immunocomplexes were collected with protein A/G agarose
beads and eluted. Cross-links were reversed by incubating at 65°C. DNA was extracted and
purified for PCR using primers (see Supplemental Experimental Procedures) corresponding
to the 3800 to 3697 base pairs upstream of the VASH1 transcription start site.
Real time quantitative RT-PCR
Cells were seeded at 1.0 × 104 cells per well in 96-well plates in complete medium and
incubated at 37°C for 24 hours, and then in low-serum medium (0.5% serum) for 18 hours,
minus EGF and VEGF supplements where appropriate. Real-time quantitative RT-PCR was
performed using 50 ng total RNA isolated from treated cells using the RNeasy Mini Kit
(Qiagen). Relative expression values were obtained using the average of three reference
genes and the 2ΔΔCT method as described previously, and normalized to control for percent
fold changes (Donninger et al., 2004).
SiRNA constructs and delivery
SiRNAs were purchased from Qiagen, Dharmacon (Chicago, IL) or Sigma-Aldrich
(Woodlands, TX). A non-silencing siRNA that did not share sequence homology with any
known human mRNA based on a BLAST search was used as control for target siRNA, and
the same sequence with Alexa-555 tag was used to determine uptake and distribution in
tumor and other organs in vivo. In vitro transient transfection was performed as described
previously (Landen et al., 2005).
DNA extraction and methylation analysis
Following DNA extraction, methylation analysis was done using a methylation kit (EZ-96
gold; Zymo Research, Orange, CA). MethPrimer software was used for the prediction of
CpG island of Mm VASH1 and design of methylation specific primers (methylated VASH1
promoter: TTAGGGATTTACGTATCGACGT (forward); AAACGACAAACTCCAACCG
(reverse); and unmethlyated VASH1 promoter:
TTTTTTTTAGGGATTTATGTATTGATGT (forward);
CTAAACAACAAACTCCAACCACA (reverse). PCR conditions were 94°C for 5 min with
hot start, then 94°C for 45 s, 56°C for 45 s, and 72°C for 45 s (40 cycles). Image analysis
(Scion Image for Windows) was used for semi-quantitative measurement of methylated and
unmethylated VASH1. Methylated VASH1 was normalized to unmethylated VASH1. The
experiments were repeated 3 times.
Orthotopic in vivo model of ovarian cancer and tissue processing
Female athymic nude mice (NCr-nu) were purchased from the NCI-Frederick Cancer
Research and Development Center (Frederick, MD) and maintained as previously described
(Landen et al., 2005). All mouse studies were approved by the Institutional Animal Care and
Use Committee. Mice were cared for in accordance with guidelines set forth by the
American Association for Accreditation of Laboratory Animal Care and the US Public
Health Service Policy on Human Care and Use of Laboratory Animals. For intra-ovarian
injection, SKOV3ip1 cells (1 × 106) were injected directly into the left ovarian parenchyma
through a left flank incision, as previously described (Lu et al., 2008). For therapy
experiments, each siRNA was given twice weekly at a dose of 150 μg/kg body weight. At
the time of sacrifice, mouse and tumor weight, number and distribution of tumors were
recorded. Individuals who performed the necropsies were blinded to the treatment group
assignments. Tissue specimens were fixed either with formalin, OCT; Miles, Inc., Elkhart,
IN) or snap frozen in liquid nitrogen.
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Immunofluorescence and confocal microscopy
Staining for EZH2, CD31, desmin, and ASMA was performed using frozen tissue as
described previously (Lu et al., 2007b). Pericyte coverage was determined by the percent of
vessels with 50% or more coverage of desmin-or ASMA-positive cells in 5 random fields at
x200 magnification for each tumor.
Optical Imaging
Nude mice bearing HeyA8 tumors (i.p.) were given Cy 5.5 labeled siRNA/CH (n=5) or
unlabeled siRNA/CH (n=6) i.v., or nothing (n=2). Forty-eight hours later, fluorescence
imaging of excised tumor and organs was performed using the Xenogen IVIS 200 system.
Cy5.5 fluorophore excitation (λexcitation=678 nm) and emission (λemission=703 nm) filter sets
were used. Using Living image 2.5 software, regions of interest (ROI) were drawn for each
organ and total flux (photons/second or p/s) was measured as photons/s/cm2/steradian (p/s/
cm2/Sr).
Western blot analysis
Western blot analysis was performed as previously reported (Halder et al., 2006; Landen et
al., 2005).
Immunohistochemical staining
To quantify MVD in the mouse tumor samples, the number of blood vessels staining
positive for CD31 (1:800 dilution, Pharmingen, San Diego, CA) was recorded in 10 random
0.159 mm2 fields at x200 magnification (Thaker et al., 2006). All staining was quantified by
2 investigators in a blinded fashion. For human ovarian cancer samples,
immunohistochemistry for EZH2 (1:400 dilution, Zymed, San Francisco, CA), CD34 (1:20
dilution, BioGenex Laboratories, San Ramon, CA (Ali-Fehmi et al., 2005; Des Guetz et al.,
2006; Ino et al., 2006), VEGF (1:100 dilution, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA), desmin (1:200 dilution, Dako, Carpinteria, CA), ASMA (1:500 dilution, Abcam,
Cambridge, MA), VASH1 (1:200 dilution, Abcam, Cambridge, MA), or NG2 (1:500
dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA) was performed, as described
previously (Ali-Fehmi et al., 2005). For EZH2 and VEGF, the stained slides were scored by
two investigators on the basis of the histochemical score (H-score; >100 defined as high
expression and ≤100, low expression), according to the method described by McCarty, et al.
(Ali-Fehmi et al., 2005; McCarty et al., 1985; Merritt et al., 2008), which considers both the
intensity of staining and the percentage of cells stained. MVD and pericyte coverage in
clinical samples was quantified as described above.
Human ovarian cancer specimens
Following approval by the Institutional Review Board, 180 paraffin-embedded epithelial
ovarian cancer specimens (collected between 1985 – 2004) with available clinical outcome
data and confirmed diagnosis by a board-certified gynecologic pathologist were obtained
from the Karmanos Cancer Institute tumor bank. The study was exempt from informed
consent since it used previously collected residual tissue samples.
Statistical analysis
Differences in continuous variables were analyzed using the Mann-Whitney rank sum or t-
test. The relationship between EZH2 expression and MVD was determined using the
Wilcoxon ranked sums test. Statistical analyses were performed using SPSS 12.0 for
Windows® (SPSS Inc., Chicago, IL). A 2-tailed p < 0.05 was considered statistically
significant. Kaplan-Meier survival plots were generated and comparisons made using the
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log-rank statistic. Bivariate orthogonal regression was used to describe the correlation
between tumor and endothelial EZH2 expression (H-score).
Highlights
• EZH2 is a key regulator of tumor angiogenesis.
• VEGF stimulation increases EZH2 levels in endothelial cells.
• EZH2 silencing inhibits angiogenesis by activating VASH1.
• EZH2 targeting is an attractive therapeutic approach.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. EZH2 expression in human ovarian carcinoma
(A) Representative images of human tumors with low and high EZH2 expression based on
immunohistochemical staining. Scale bar = 50 μm.
(B) Kaplan-Meier curves of disease-specific mortality for patients whose ovarian tumors
expressed high or low levels of EZH2 (EZH2-T). The log-rank test (two-sided) was used to
compare differences between the two groups. Increased EZH2-T was significantly
associated with decreased overall survival (p < 0.001).
(C) Representative images of human ovarian cancer vasculature (arrowheads point to
endothelial cells) with low or high immunohistochemical staining for EZH2. Scale bar = 25
μm. Insets show blood vessels at higher magnification.
(D) Kaplan-Meier curves of disease-specific mortality of patients whose ovarian vasculature
expressed low versus high EZH2 (EZH2-Endo). High EZH2-Endo expression was
predictive of poor overall survival.
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(E) Representative images of human epithelial ovarian cancers with low or high
immunohistochemical staining for VEGF. Scale bar = 50 μm.
(F) VEGF expression was strongly associated with high EZH2-Endo expression levels.
(G) Representative images of human ovarian cancers with low or high
immunohistochemical staining for microvessel density (MVD). Scale bar = 100 μm.
(H) Differences in mean MVD based on EZH2-Endo expression levels in human epithelial
ovarian cancers.
(I) VEGF increases EZH2 in endothelial cells. Results are in response to 6-hour treatment
with VEGF (50 ng/mL), or conditioned medium (CM) from the non-cancerous ovarian
epithelial cell line IOSE120, or the SKOV3 ovarian cancer cells. Fold changes represent the
mean of triplicate experiments compared to untreated control cells. *p < 0.01. EZH2
promoter activity and mRNA levels are increased in mouse ovarian endothelial cells
(MOEC) in response to VEGF, or conditioned media from ovarian cancer cells.
Error bars indicate SD.
See also Figure S1.
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Figure 2. EZH2 gene silencing increases VASH1 mRNA expression in endothelial cells
(A) ChIP assay of EZH2 binding to VASH1 promoter in response to VEGF in mouse
ovarian endothelial cells (MOEC). Cross-linked chromatin from MOEC was treated with (+)
or without (−) VEGF and immunoprecipitated (IP) using EZH2 or mouse IgG antibodies.
The input and immunoprecipitated DNA were subjected to PCR using primers
corresponding to the 3800 to 3584 base pairs upstream of VASH1 transcription start site.
PCR products were examined on ethidium bromide-stained agarose gel.
(B) Quantitative ChIP assay of EZH2 binding to VASH1 promoter in response to VEGF in
endothelial cells. Treatment conditions are similar to those described in Panel A. PCR
products were examined by Roche SYBR Green System for quantitative PCR.
(C) MOECs were transfected with control or mouse EZH2 siRNA (two different sequences)
and harvested after 72 hours. Untransfected (UT) cells were used as controls. RNA was
isolated and subjected to real-time quantitative RT-PCR. The fold difference represents the
mean of triplicate experiments compared to control siRNA treated cells. *p < 0.01.
(D) Fold change in VASH1 mRNA levels in MOEC following transfection with either
control or EZH2 siRNA (two different sequences). *p < 0.01.
(E) The effect of EZH2 gene silencing on VASH1 methylation in VEGF-treated MOECs
was detected by methylation specific PCR. The inhibitory units of methylated VASH1 were
normalized by that of the un-methylated VASH1 and represent the mean of triplicate
experiments. *p < 0.05.
(F) Western blot of lysate collected 48 hours after transfection of MOEC with control,
VEGF treated and mouse EZH2 siRNA treated cells.
Error bars indicate SEM.
See also Figure S2.
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Figure 3. E2F mediated regulation of EZH2 and VASH1
(A) Expression levels of E2F transcription factors in mouse ovarian endothelial cells
(MOEC) following treatment with VEGF. *p < 0.01.
(B) Effect of VEGF and either control, E2F1, or E2F3 siRNA (two different sequences) on
EZH2 mRNA levels. The fold change in levels of mRNA expression represents the mean of
triplicate experiments. *p < 0.01.
(C) Quantitative ChIP assay of E2F1 and E2F3 binding to EZH2 promoter in response to
VEGF in MOEC. Crosslinked chromatin from MOECs treated with (+) or without (−)
VEGF 50 ng/mL was immunoprecipitated using E2F1, E2F3, or mouse IgG antibodies. The
input and immunoprecipitated DNA were subjected to PCR using primers corresponding to
the 442 to 151 base pairs upstream of EZH2 transcription site. PCR products were examined
by Roche SYBR Green System for quantitative PCR.
(D) Crosslinked chromatin from MOECs treated with (+) or without (−) indicated siRNA
and with (+) or without (−) VEGF 50 ng/mL was immunoprecipitated using EZH2 or mouse
IgG antibodies. The input and immunoprecipitated DNA were subjected to PCR using
primers corresponding to the 3800 to 3584 base pairs upstream of VASH1 transcription site.
PCR products were examined by Roche SYBR Green System for quantitative PCR.
Error bars indicate SEM.
See also Figure S3.
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Figure 4. In vivo siRNA delivery using chitosan (CH) nanoparticles
Distribution of siRNA following single intravenous injection of Alexa-555 siRNA/CH
nanoparticles in orthotopic HeyA8 tumor bearing nude mice. Fluorescent siRNA distribution
in tumor tissue:
(A) Hematoxylin and eosin, original magnification x200 (left); tumor tissues were stained
with anti-CD31 (green) antibody to detect endothelial cells (right). Scale bar = 50 μm.
(B) Sections (8-μm thick) were stained with sytox green and examined with confocal
microscopy (scale bar 20 μm) (left); lateral view (right). Photographs taken every 1 μm were
stacked and examined from the lateral view. Nuclei were labeled with sytox green and
fluorescent siRNA (red) was seen throughout the section. At all time points, punctated
emissions of the siRNA were noted in the perinuclear regions of individual cells, and siRNA
was seen in >80% of fields examined.
(C–D) Optical imaging of organs and tumors from HeyA8 tumor-bearing mice treated with
either Cy5.5 siRNA/CH or unlabeled siRNA/CH. (C) Fluorescence intensity overlaid on
white light images of different mouse organs and tumor. (D) Semi-quantitative evaluation of
fluorescence intensity in different mouse organs. Error bars indicate SD. *p < 0.05;**p <
0.01.
See also Figure S4.
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Figure 5. Effects of EZH2 gene silencing on in vivo ovarian cancer growth
(A) Western blot of lysates from orthotopic tumors collected 24, 48, 72 and 96 hours after a
single injection of control siRNA/CH or human (EZH2 Hs siRNA/CH).
(B) EZH2 gene silencing in HeyA8 tumor as well as tumor endothelial cells. Tumors
collected after 48 hours of single injection of control siRNA/CH, or EZH2 Hs siRNA/CH, or
EZH2 Mm siRNA/CH and stained for EZH2 (green) and CD31 (red). Scale bar = 50 μm.
(C) Effects of EZH2 Hs siRNA/CH or EZH2 Mm siRNA/CH on tumor weight in orthotopic
mouse models of ovarian cancer. Error bars indicate SEM. *p < 0.05; **p < 0.001.
See also Table S1; Figure S5.
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Figure 6. Effect of EZH2 targeting on tumor vasculature
(A) Effect of tumor (EZH2 Hs siRNA/CH) or endothelial (EZH2 Mm siRNA/CH) targeted
EZH2 siRNA on microvessel density (MVD) and pericyte coverage. Tumors harvested
following 4 to 5 weeks of therapy were stained for CD31 (MVD; red) and desmin (pericyte
coverage; green). Scale bar = 50 μm. The bars in the graphs correspond sequentially to the
labeled columns of images at left. *p < 0.01; **p < 0.001.
(B) Effects of VASH1 gene silencing on tumor growth in vivo. Nude mice injected with
SKOV3ip1 ovarian cancer cells into the peritoneal cavity were randomly divided into 6
groups (10 mice per group): (1) control siRNA/CH (control si), (2) EZH2 Mm siRNA1/CH
(EZH2-1 si), (3) EZH2 Mm siRNA2/CH (EZH2-2 si) (4) EZH2 Mm siRNA3/CH (EZH2-3
si) (5) VASH1 Mm siRNA1/CH (VASH1 si) and (6) combination of EZH2 Mm siRNA1/
CH plus VASH1 Mm siRNA/CH. *p < 0.05. MVD is shown graphically in the adjacent
graph.
(C) Endothelial VASH1 protein expression is plotted against endothelial EZH2 expression
in 37 epithelial ovarian cancer specimens. The best-fit linear regression model is depicted
with 95% confidence limits (R2=−0.59, p < 0.001). The linear lines intersecting with 100 on
each axis represent predetermined cut-off values of “high” vs. “low” expression. The
presence of EZH2 expression was associated with low expression of VASH1, which was
otherwise elevated in the absence of or in the presence of low EZH2 expression.
(D) VASH1 mRNA levels were measured in endothelial cells isolated from normal ovarian
(n=3), and epithelial ovarian cancer (n=10) samples using quantitative RT-PCR. The final
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mRNA levels in the tumor endothelial cells were converted to ratios of decreased ( 1) or
increased (≤1) relative to levels of mRNA in normal ovarian endothelial cells (*p < 0.01).
(E) Vessel maturation was examined by determining the extent of pericyte coverage in
human epithelial ovarian cancer samples using an anti-alpha smooth muscle actin (ASMA)
antibody. *p < 0.01.
Error bars indicate SEM.
See also Table S2; Figure S6.
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Figure 7.
Analysis of putative EZH2 pathways in cancer-associated endothelial cells. Pathway
diagrams were generated with the assistance of Pathway Studio software (Ariadne,
Rockville, MD). A model is reported in which VEGF stimulation leads to increased
expression of E2F transcription factors, which directly modulates EZH2 levels. EZH2, a
transcriptional repressor, causes VASH1 silencing by promoter methylation and
subsequently increases angiogenesis.
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